JP2022062170A5 - - Google Patents

Download PDF

Info

Publication number
JP2022062170A5
JP2022062170A5 JP2022015456A JP2022015456A JP2022062170A5 JP 2022062170 A5 JP2022062170 A5 JP 2022062170A5 JP 2022015456 A JP2022015456 A JP 2022015456A JP 2022015456 A JP2022015456 A JP 2022015456A JP 2022062170 A5 JP2022062170 A5 JP 2022062170A5
Authority
JP
Japan
Prior art keywords
once
pharmaceutical composition
year
composition according
arc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022015456A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022062170A (ja
Filing date
Publication date
Priority claimed from JP2020153037A external-priority patent/JP7021314B2/ja
Application filed filed Critical
Publication of JP2022062170A publication Critical patent/JP2022062170A/ja
Publication of JP2022062170A5 publication Critical patent/JP2022062170A5/ja
Priority to JP2023174548A priority Critical patent/JP7559175B6/ja
Pending legal-status Critical Current

Links

JP2022015456A 2016-02-12 2022-02-03 Hivおよびエイズの治療および予防方法 Pending JP2022062170A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023174548A JP7559175B6 (ja) 2016-02-12 2023-10-06 Hivおよびエイズの治療および予防方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662294576P 2016-02-12 2016-02-12
US62/294,576 2016-02-12
US201662297657P 2016-02-19 2016-02-19
US62/297,657 2016-02-19
JP2020153037A JP7021314B2 (ja) 2016-02-12 2020-09-11 Hivおよびエイズの治療および予防方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020153037A Division JP7021314B2 (ja) 2016-02-12 2020-09-11 Hivおよびエイズの治療および予防方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023174548A Division JP7559175B6 (ja) 2016-02-12 2023-10-06 Hivおよびエイズの治療および予防方法

Publications (2)

Publication Number Publication Date
JP2022062170A JP2022062170A (ja) 2022-04-19
JP2022062170A5 true JP2022062170A5 (enExample) 2022-07-14

Family

ID=58057333

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018541685A Active JP6810972B2 (ja) 2016-02-12 2017-02-10 Hivおよびエイズの治療および予防方法
JP2020153037A Active JP7021314B2 (ja) 2016-02-12 2020-09-11 Hivおよびエイズの治療および予防方法
JP2022015456A Pending JP2022062170A (ja) 2016-02-12 2022-02-03 Hivおよびエイズの治療および予防方法
JP2023174548A Active JP7559175B6 (ja) 2016-02-12 2023-10-06 Hivおよびエイズの治療および予防方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2018541685A Active JP6810972B2 (ja) 2016-02-12 2017-02-10 Hivおよびエイズの治療および予防方法
JP2020153037A Active JP7021314B2 (ja) 2016-02-12 2020-09-11 Hivおよびエイズの治療および予防方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023174548A Active JP7559175B6 (ja) 2016-02-12 2023-10-06 Hivおよびエイズの治療および予防方法

Country Status (37)

Country Link
US (4) US10537589B2 (enExample)
EP (1) EP3413897B1 (enExample)
JP (4) JP6810972B2 (enExample)
KR (4) KR20220126787A (enExample)
CN (2) CN108697727A (enExample)
AU (3) AU2017217656B2 (enExample)
BR (1) BR112018016349A2 (enExample)
CA (1) CA3013473C (enExample)
CL (1) CL2018002150A1 (enExample)
DK (1) DK3413897T3 (enExample)
DO (1) DOP2018000183A (enExample)
EA (1) EA201891814A1 (enExample)
ES (1) ES2953535T3 (enExample)
FI (1) FI3413897T3 (enExample)
GE (1) GEP20217231B (enExample)
HR (1) HRP20230935T1 (enExample)
HU (1) HUE063532T2 (enExample)
IL (1) IL260874B2 (enExample)
JO (1) JOP20170038B1 (enExample)
LT (1) LT3413897T (enExample)
MD (1) MD3413897T2 (enExample)
MX (3) MX390604B (enExample)
MY (1) MY197090A (enExample)
NI (1) NI201800083A (enExample)
NZ (1) NZ745065A (enExample)
PH (1) PH12018501712A1 (enExample)
PL (1) PL3413897T3 (enExample)
PT (1) PT3413897T (enExample)
RS (1) RS64448B1 (enExample)
SG (1) SG11201806783WA (enExample)
SI (1) SI3413897T1 (enExample)
SV (1) SV2018005733A (enExample)
TN (1) TN2018000267A1 (enExample)
TW (2) TWI822652B (enExample)
UA (1) UA126375C2 (enExample)
WO (1) WO2017139519A1 (enExample)
ZA (1) ZA201805073B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20170038B1 (ar) * 2016-02-12 2021-08-17 Merck Sharp & Dohme مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه
US20200138845A1 (en) * 2017-07-18 2020-05-07 Viiv Healthcare Company Combination Drug Therapy
US12297224B2 (en) * 2018-07-02 2025-05-13 Henan Genuine Biotech Co., Ltd. Crystal form, preparation method, and application of 4'-substituted nucleoside
US12005072B2 (en) 2018-07-17 2024-06-11 Merck Sharp & Dohme Llc HIV drug combination for increasing barrier against resistance
AU2019403024A1 (en) * 2018-12-20 2021-07-15 Merck Sharp & Dohme Llc Novel crystalline forms of an NRTTI compound
PH12021551734A1 (en) 2019-01-25 2022-07-25 Univ Brown Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders
EP3934760A1 (en) * 2019-03-06 2022-01-12 GlaxoSmithKline Intellectual Property (No.2) Limited Compounds useful in hiv therapy
WO2021021717A1 (en) 2019-07-27 2021-02-04 Brii Biosciences, Inc. Adenosine derivative and pharmaceutical composition comprising the same
WO2023196832A2 (en) * 2022-04-06 2023-10-12 Brii Biosciences, Inc. Pharmaceutical composition and method for treatment of human immunodeficiency virus infections

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0831852B1 (en) * 1995-06-07 2006-11-29 Emory University Nucleosides with anti-hepatitis b virus activity
US7589078B2 (en) 2003-02-19 2009-09-15 Yale University Anti-viral nucleoside analogs and methods for treating viral infections, especially HIV infections
CA2502109C (en) * 2004-03-24 2010-02-23 Yamasa Corporation 4'-c-substituted-2-haloadenosine derivative
WO2009126293A2 (en) * 2008-04-11 2009-10-15 Yale University Potent chimeric nrti-nnrti bifunctional inhibitors of hiv-1 reverse transcriptase
US9289445B2 (en) * 2011-01-20 2016-03-22 University Of Rochester Compositions and methods for treating or preventing a retrovirus infection
WO2015143712A1 (en) 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
JP6768796B2 (ja) 2015-09-23 2020-10-14 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. 4’−置換ヌクレオシド逆転写酵素阻害剤及びその調製
JOP20170038B1 (ar) * 2016-02-12 2021-08-17 Merck Sharp & Dohme مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه
BR112018072883B1 (pt) * 2016-05-12 2023-01-17 Merck Sharp & Dohme Llc Sistema de implante subdérmico do agente antiviral 4'-etinil-2-fluoro-2'-desoxiadenosina com polímero eva e seu uso
EP3471829A4 (en) * 2016-06-20 2020-01-15 Merck Sharp & Dohme Corp. ACTIVE SUBSTANCE RELEASE SYSTEM FOR RELEASING VIRUZIDS
US20200138845A1 (en) * 2017-07-18 2020-05-07 Viiv Healthcare Company Combination Drug Therapy
JOP20220033A1 (ar) * 2019-08-13 2023-01-30 Merck Sharp & Dohme نظام توصيل أدوية لتوصيل العوامل المضادة للفيروسات
EP4146302A4 (en) * 2020-05-05 2024-05-22 Merck Sharp & Dohme LLC DRUG DELIVERY SYSTEM FOR DELIVERY OF ANTIVIRAL AGENTS AND CONTRACEPTIVES
US20230310309A1 (en) * 2020-08-25 2023-10-05 Merck Sharp & Dohme Llc Injectable depot compositions for the delivery of antiviral agents

Similar Documents

Publication Publication Date Title
JP2022062170A5 (enExample)
JP2022009090A5 (enExample)
JP2021001189A5 (enExample)
RU2329050C2 (ru) Комбинация ингибиторов цитохром-р450-зависимых протеаз
HRP20230935T1 (hr) Postupci za liječenje i profilaksu hiv-a i aids-a
JP2024133474A5 (enExample)
JP2019536805A5 (enExample)
JP2020505423A5 (enExample)
RU2010104848A (ru) Кристаллическая форма 4-[[4-[[4-(2-цианоэтенил)-2,6-диметилфенил]амино]-2-пиримидинил]амино]бензонитрила
JP2019517542A5 (enExample)
JP2016185995A5 (enExample)
RU2011127080A (ru) Производное циклоспорина для применения в лечении заражения вирусом гепатита с и вич
IL300151A (en) Combinations for the treatment of cancer
JP2017514911A5 (enExample)
JP2018530578A5 (enExample)
RU2016114098A (ru) Новое производное аналога инсулина
JP2019218379A5 (enExample)
JP2021004249A5 (enExample)
JPWO2020261093A5 (enExample)
TWI760306B (zh) 供治療癌症之口服投予紫杉醇及P-gp抑制劑的治療性組合
JPWO2020257671A5 (enExample)
CN104622927A (zh) 外用消炎粉
JP2019531286A5 (enExample)
JP2019535830A5 (enExample)
JP2006508118A5 (enExample)